Compare Ascendis Pharma A/S (ASND) vs ArcelorMittal SA (MT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs ArcelorMittal SA — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while ArcelorMittal SA trades at $66.41 (market cap $49.99B). The key difference: ArcelorMittal SA is far larger — about 2.8× Ascendis Pharma A/S's market cap, and ArcelorMittal SA pays a 0.91% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MT | |
|---|---|---|
Market Cap | $17.74B | $49.99B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $71.65 |
52-Week Low | $163.32 | $30.39 |
Enterprise Value | $18.11B | $59.31B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ArcelorMittal (MT) trades at $66.08, up 4.96% today, with strong earnings beats in recent quarters. The stock shows bullish momentum with a 41% gain over six months, supported by record iron ore shipments and strategic expansions. Valuation ratios appear reasonable with P/E at 17.3 and P/B below 1. Technical indicators are mixed, with moving averages bullish but oscillators neutral. Recent news highlights CEO transitions in Europe and a new share buyback program.
Outlook remains positive due to operational strength and shareholder returns, but risks include heavy capital expenditure and China demand weakness. Analyst consensus is bullish with 50% buy ratings. The stock's performance hinges on continued execution amid global steel market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
